Skip directly to content

Lower Risk in Other Breast

 

Inspired to Be Informed

 

Lower Risk in Other Breast

The risk of developing cancer in the other breast was lower for women who switched to AROMASIN® (exemestane tablets) after 2 to 3 years of treatment with tamoxifen than for women who stayed on tamoxifen for 5 years.

Women who developed cancer in the other breast after almost
3 years (34.5 months) in the study
AROMASIN
Patients
(n=2,352)
7
Tamoxifen
Patients
(n=2,372)
25

Absolute risk reduction

Fewer (0.8% less) women developed cancer in the other breast in the AROMASIN group than in the tamoxifen group

Relative risk reduction

68% lower risk of
developing cancer
in the other breast

Relative risk reduction: helps us understand the likelihood (risk) of disease recurrence for patients who switched to AROMASIN versus patients who stayed on tamoxifen.

Almost 5 years in the study, results continued

Women who developed cancer in the other breast after almost
5 years (52.4 months) in the study
AROMASIN
Patients
(n=2,352)
18
Tamoxifen
Patients
(n=2,372)
35

Absolute risk reduction

Fewer (0.7% less) women developed cancer in the other breast in the AROMASIN group than in the tamoxifen group

Relative risk reduction

43% lower risk of
developing cancer
in the other breast

Relative risk reduction: helps us understand the likelihood (risk) of disease recurrence for patients who switched to AROMASIN versus patients who stayed on tamoxifen.